Bristol-Myers Squibb Co. (BMY)

55.53
NYSE : Health Technology
Prev Close 55.21
Day Low/High 54.90 / 56.47
52 Wk Low/High 42.48 / 68.34
Avg Volume 16.06M
Exchange NYSE
Shares Outstanding 2.26B
Market Cap 124.03B
EPS 2.00
P/E Ratio 27.47
Div & Yield 1.80 (3.06%)

Latest News

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Watch These Biotech Names on Strong Earnings

Watch These Biotech Names on Strong Earnings

Merger activity is the number 1 driver I am watching for biotech growth.

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

China Reduces Tariffs, 20 Year Treasury Bonds, Pricey Peloton: Market Recon

This move by Beijing comes on top of massive injections of liquidity into that nation's financial system earlier this week.

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

Decisions, Decisions: AbbVie or Bristol-Myers Squibb?

AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

Jim Cramer: Larry Fink Is Showing What True Leadership Looks Like

Jim Cramer: Larry Fink Is Showing What True Leadership Looks Like

BlackRock's CEO will now make investment decisions based on a company's commitment to environmental sustainability. You can bet the financial world will never be the same again.

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

Jim Cramer: The HQ for Innovation Is Right Here in San Francisco

The NYSE used to be the center of capitalism, but now it's where actual engineering, not financial engineering, is taking place.

Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter

Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter

Let's review the charts.

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

Jim Cramer: Don't Get Sacked in This Political Football Match

Jim Cramer: Don't Get Sacked in This Political Football Match

How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later

Bristol-Myers Squibb May Trade Sideways for a Bit but Expect New Highs Later

The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.

3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

Jim Cramer: Why Doesn't Impeachment Matter More to the Market?

Jim Cramer: Why Doesn't Impeachment Matter More to the Market?

The impeachment and trial of President Trump has nothing to do with the price to earnings ratio of Bristol-Myers or any other stock for that matter.

3 Biotech Stocks With the Best-Looking Charts

3 Biotech Stocks With the Best-Looking Charts

Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.

Jim Cramer: Be Cautious Today, the Tape Feels Bad

Jim Cramer: Be Cautious Today, the Tape Feels Bad

We are playing defense as we see some downward pressure on oil and healthcare weakness.

Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

We're seeing lots of companies snapping up their peers, and the market is applauding.

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Bristol-Myers Stock Has the Right Prescription

Bristol-Myers Stock Has the Right Prescription

BMY can soar still higher in the months ahead.

Fed's Action, Consumer Remains Robust, Unimpressive Twilio: Market Recon

Fed's Action, Consumer Remains Robust, Unimpressive Twilio: Market Recon

I do think that this Fed Chair has learned to be cautious, in reflection of the policy errors made in late 2018.

Make Fed Day a Time for Paper Trades

Make Fed Day a Time for Paper Trades

Traders can learn from watching, as well as doing, and with the FOMC meeting landing, now's best time to practice the former.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

If Estée Lauder Beats on Earnings, Expect Rally Ahead

If Estée Lauder Beats on Earnings, Expect Rally Ahead

The price of EL has corrected lower, and if its quarterly report or guidance is better than expected, we should the uptrend resume.

Big Biotech Receives Some Needed Shots in the Arm

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.